CHG-CVAI

1. CHG-CVAI is associated with cardiovascular disease in humans (CKM stages 0–3; CHARLS) (HR 1.221, 95% CI 1.154–1.292 per SD increase).

   “and CHG-CVAI with 1.221 (1.154–1.292) and 1.226 (1.009–1.490), respectively.”

   HumansCKM stages 0–3; CHARLSPer 1 source-sample SD increasen = 5,304

   Blood and body-size scores linked to cardiovascular risk

   Research Square·Nov 12, 2026Preprint

2. CHG-CVAI is associated with cardiovascular disease in humans (17% higher CVD risk per 1-SD rise).

   “Per 1‐SD rise in baseline CHG‐WC and CHG‐CVAI corresponded to 19% and 17% higher CVD risk, respectively.”

   HumansPer 1-SD rise in baseline CHG-CVAI8-year median follow-upn = 4,164

   Trajectories of a Composite Lipid, Glucose, and Refined Obesity Index Predict Cardiovascular Disease

   Cardiovascular therapeutics·Nov 4, 2026

More on Cardiovascular disease

1. CHG-CVAI is associated with cardiovascular mortality in humans (CKM stages 0–3; NHANES) (HR 1.226, 95% CI 1.009–1.490 per SD increase).

   “and CHG-CVAI with 1.221 (1.154–1.292) and 1.226 (1.009–1.490), respectively.”

   HumansCKM stages 0–3; NHANESPer 1 source-sample SD increasen = 5,487

   Blood and body-size scores linked to cardiovascular risk

   Research Square·Nov 12, 2026Preprint

1. CHG-CVAI is associated with incident cardiovascular disease in humans (without baseline cardiovascular disease; fully adjusted Model 3) (HR 1.213, 95% CI 1.154–1.275 per 1-SD increment).

   “with the largest estimate for CHG-CVAI (HR 1.213, 95% CI 1.154-1.275).”

   Humanswithout baseline cardiovascular disease; fully adjusted Model 3per 1-SD increment9 yearsn = 7,516

   Endpoint-specific associations of the cholesterol, high-density lipoprotein, and glucose (CHG) index and its adiposity- and inflammation-related derivatives with incident cardiovascular disease and mortality: evidence from CHARLS and NHANES

   Cardiovascular diabetology·Aug 17, 2026

More on Incident cardiovascular disease